Raul Santos: International Collaborative Insights into the Treatment of Homozygous FH
Raul Santos, Researcher at ARO Hospital Israelita Albert Einstein, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
“The therapy of Homozygous FH (HoFH) is a great challenge due to the extreme elevated LDL-C levels and the genetic variability that characterizes this disease.
Combination therapy is the rule to reduce LDL-C, and is classified in medications that depend on the LDL receptor function like statins, ezetimibe and PCSK9 inhibitors and those who are independent like Lomitapide and Evinacumab.
In this collaborative study between Canada, South Africa and Brazil led by John Mancini we showed that statins also reduce LDL-C by mechanisms other than depending on the LDL receptor alone.
HoFH is a devastating disease that needs to be diagnosed and treated ASAP.
Novel therapies are coming and hopefully will change for good how we treat this disease!”
Article: Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype.
Authors: G.B.John Mancini, Arnold Ryomoto, Isabelle Ruel, Iulia Iatan, Jacques Genest, Frederick J. Raal, Raul D. Santos, Ana Paula Marte, Brooke A. Kennedy, Liam R. Brunham, Daniel Gaudet, Miriam Larouche, Diane Brisson, Robert A. Hegele
Read the Full Article on Atherosclerosis
Stay updated on all scientific advances with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies